Related Experiment Video
Updated: Jan 30, 2026

Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding
Published on: August 30, 2024
Pulmonary Artery Banding in Post-tricuspid Congenital Cardiac Shunting Defects with High Pulmonary Vascular
Thomas J Kulik1,2, Julia E McSweeney3, Joseph Tella4
1Division of Cardiac Critical Care, and the Pulmonary Hypertension Program, Department of Cardiology, Boston Children's Hospital, 300 Longwood Ave, Boston, MA, 02115, USA. thomas.kulik@cardio.chboston.org.
Insights
Treating post-tricuspid cardiac shunts with high pulmonary vascular resistance (PVR) using pulmonary artery banding is challenging. Many patients do not achieve sufficient PVR reduction, and PVR can increase long-term after repair.
Area of Science:
- Cardiology
- Pediatric Cardiology
- Pulmonary Hypertension
Background:
- "Treat and repair" strategies for cardiac shunts with inoperably high pulmonary vascular resistance (PVR) are complex, especially for post-tricuspid defects.
- Pulmonary artery (PA) banding is a palliative approach, but its efficacy in significantly reducing PVR in these cases is debated.
Purpose of the Study:
- To evaluate the effectiveness of PA banding and targeted pulmonary hypertension medications in patients with large ventricular septal defects (VSDs) and inoperably high PVR.
- To review previous reports on PA banding for post-tricuspid defects to assess long-term outcomes.
Main Methods:
- Retrospective analysis of 5 patients with large VSDs and high PVR treated with PA banding and medications.
- Review of existing literature on PA banding for post-tricuspid defects.
Main Results:
- Three patients had persistent high mean pulmonary artery pressure (>50 mmHg) post-banding with minimal PVR reduction.
- Two patients achieved lower PVR post-banding and underwent VSD closure, but experienced progressive PVR increase over 3.5 and 7.7 years.
- Previous reports indicate difficulty in achieving adequate band gradients and limited success in surgical repair post-banding.
Conclusions:
- PA banding for post-tricuspid defects with high PVR is technically challenging, often failing to achieve sufficient PVR reduction.
- Long-term PVR monitoring is crucial as it can increase significantly even after successful defect closure.
- Further research is needed, emphasizing accurate pre-treatment characterization of pulmonary circulation and long-term follow-up.
Abstract:
Reports of "treat and repair" of cardiac shunting lesions with inoperably high pulmonary vascular resistance (PVR) mostly concern pre-tricuspid defects; post-tricuspid lesions are different. We report our experience with pulmonary artery (PA) banding ± targeted pulmonary hypertension medications in five patients with a large VSD and inoperably high PVR, and review previous reports of PA banding with post-tricuspid defects. Three of our 5 patients had mean PAP > 50 mmHg after banding and no or only a transient fall in PVR. Two patients had mean PAP < 50 mmHg and lower PVR after banding; they had closure of their VSDs but have since had a progressive increase in PVR (follow-up after closure, 3.5 and 7.7 years). Previous reports have also documented difficulty in achieving sufficient band gradient. Of previously reported patients, only one became operable only after banding and targeted therapy, and was repaired; follow-up after repair was short-term (16 months). Our and previous experience demonstrate the difficulty in placing a PA band sufficiently tight to substantially reduce PA pressure. Reported attempts to "treat and repair" post-tricuspid defects are few and have met with limited success, and we found that PVR may increase significantly over time after repair. But more information is needed. Accurate interpretation of experience with "treat and repair" requires: careful characterization of the pulmonary circulation prior to "treating"; considering spontaneously reversible factors at pre-treatment catheterization before ascribing reduction in PVR to medical therapy; and long-term observation of PVR in patients who have had defect closure.
More Related Videos
09:23Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension
Published on: February 11, 2017
07:02A Large Animal Model for Pulmonary Hypertension and Right Ventricular Failure: Left Pulmonary Artery Ligation and Progressive Main Pulmonary Artery Banding in Sheep
Published on: July 15, 2021
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Vascular Resistance
The primary determinants of vascular resistance are vessel diameter, blood viscosity, and vessel length. Among these, vessel diameter plays the most significant role due to the fourth power relationship described by...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...